Evaluation of three consecutive versions of a commercial rapid PCR test to screen for methicillin-resistant Staphylococcus aureus.

Details

Ressource 1Download: 1-s2.0-S1198743X19301508-main.pdf (271.83 [Ko])
State: Public
Version: Author's accepted manuscript
License: Not specified
Serval ID
serval:BIB_EC5E10DF321A
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Evaluation of three consecutive versions of a commercial rapid PCR test to screen for methicillin-resistant Staphylococcus aureus.
Journal
Clinical microbiology and infection
Author(s)
Bulliard E., Grandbastien B., Senn L., Greub G., Blanc D.S.
ISSN
1469-0691 (Electronic)
ISSN-L
1198-743X
Publication state
Published
Issued date
11/2019
Peer-reviewed
Oui
Volume
25
Number
11
Pages
1430.e1-1430.e4
Language
english
Notes
Publication types: Comparative Study ; Evaluation Study ; Journal Article
Publication Status: ppublish
Abstract
Screening for methicillin-resistant Staphylococcus aureus (MRSA) is part of many recommendations to control MRSA. Several rapid PCR tests are available commercially and updated versions are constantly released. We aimed to evaluate the performance of three consecutive versions (G3, Gen3 and NxG) of the XpertMRSA test.
Routine samples for MRSA screening were simultaneously tested by culture and rapid PCR. The three versions of XpertMRSA were used successively and compared with culture.
A total of 3512, 2794 and 3288 samples were analysed by culture and by the G3, Gen3 and NxG XpertMRSA versions, respectively. The rates of positive-by-culture in the three groups were 5.0%, 4.7% and 4.3%, respectively. The sensitivity improved over time (71.4, 95% CI 64.0-77.9; 82.3, 95% CI 74.4-88.2; and 84.3%, 95% CI 77.0-89.7, respectively), but not significantly. The specificity (98.4, 95% CI 97.9-98.8; 96.8, 95% CI 96.0-97.4; and 99.1, 95% CI 98.7-99.4, respectively) and the positive likelihood ratios (45.7, 95% CI 34.4-60.8; 25.6, 95% CI 20.5-32.0; and 97.1, 95% CI 66.3-142.4) were significantly lower in the Gen3 version (p < 0.00001).
These significant differences in performance show the importance of evaluating each new version of a commercial test.
Keywords
Bacteriological Techniques/methods, Humans, Mass Screening/methods, Methicillin-Resistant Staphylococcus aureus/genetics, Methicillin-Resistant Staphylococcus aureus/isolation & purification, Molecular Diagnostic Techniques/methods, Polymerase Chain Reaction/methods, Sensitivity and Specificity, Staphylococcal Infections/diagnosis, Staphylococcal Infections/microbiology, Diagnostic test, Methicillin-resistant Staphylococcus aureus, Performance, Rapid PCR test, Rapid test, Screening
Pubmed
Web of science
Create date
28/04/2019 16:01
Last modification date
07/02/2020 7:19
Usage data